v3.26.3
Segment (Tables)
 9 Months Ended
Sep. 30, 2026
Single Reporting Segment  
Segment Reporting [Line Items]  
Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations

The significant expense categories within net loss are presented on the statements of operations. The research and development expenses have been disaggregated as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Research and engineering expenses

 

$

29,268

 

 

$

29,271

 

 

$

88,481

 

 

$

99,535

 

Clinical expenses

 

 

42,558

 

 

 

30,042

 

 

 

123,804

 

 

 

83,054

 

In-process research and development expenses

 

 

—

 

 

 

—

 

 

 

5,048

 

 

 

2,500

 

Total research and development expenses

 

 

71,826

 

 

 

59,313

 

 

 

217,333

 

 

 

185,089

 

General and administrative expenses

 

 

18,726

 

 

 

15,438

 

 

 

53,950

 

 

 

70,688

 

Other segment items#

 

 

(4,440

)

 

 

(3,612

)

 

 

(13,804

)

 

 

(11,184

)

Net loss

 

$

86,112

 

 

$

71,139

 

 

$

257,479

 

 

$

244,593

 

 

# Other segment items consist of interest income (expense), net and other income (expense), net.